A detailed history of Ausdal Financial Partners, Inc. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Ausdal Financial Partners, Inc. holds 684 shares of VRTX stock, worth $324,325. This represents 0.04% of its overall portfolio holdings.

Number of Shares
684
Previous 587 16.52%
Holding current value
$324,325
Previous $245,000 30.61%
% of portfolio
0.04%
Previous 0.03%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 06, 2024

BUY
$392.81 - $485.53 $38,102 - $47,096
97 Added 16.52%
684 $320,000
Q1 2024

Apr 12, 2024

BUY
$407.69 - $446.08 $38,322 - $41,931
94 Added 19.07%
587 $245,000
Q4 2023

Jan 11, 2024

BUY
$343.0 - $410.68 $169,099 - $202,465
493 New
493 $200,000
Q1 2022

May 04, 2022

SELL
$221.42 - $260.97 $3.32 Million - $3.91 Million
-14,981 Closed
0 $0
Q4 2021

Feb 08, 2022

BUY
$177.01 - $223.45 $2.65 Million - $3.35 Million
14,981 New
14,981 $3.29 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $122B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Ausdal Financial Partners, Inc. Portfolio

Follow Ausdal Financial Partners, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ausdal Financial Partners, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Ausdal Financial Partners, Inc. with notifications on news.